

# Biotech Capital.

Biotech Capital (BTC) - ASX Announcement

23 February 2017

## BIOIMPACT APPOINTS SENIOR IN-LICENSING EXECUTIVE

Biotech Capital Limited (ASX:BTC) announced today that its wholly owned subsidiary Bioimpact Pty Ltd has appointed Oskar Hakansson as Business Development Director to lead the group's in-licensing activities.

Oskar has over 25 years experience in the pharmaceutical industry working in both large and small companies in Australia and internationally. He has broad experience in product commercialisation, mergers, acquisitions, pipeline development, global product sourcing and portfolio development. He was formerly Regional Head of Cipla Pharmaceuticals (ANZ) and prior to that that held senior commercial roles with Symbion Pharmacy Services and Sigma Pharmaceuticals.

Biotech Capital is currently pursuing opportunities to in-license or acquire the rights to novel pharmaceutical therapies and medical devices. This is a key part of the group's strategy to build an integrated biomedical company with exceptional partnering, development and commercialisation capabilities across Asia-Pacific.

Biotech Capital's Chairman Dr. Richard Treagus commented; "We are fortunate to be attracting some of the very best industry talent into the Biotech Capital group. We are therefore delighted to have Oskar join us and his appointment adds tremendous strength and capability to our in-licensing activities."

### About Biotech Capital Limited

Biotech Capital is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company's strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The company has the longer-term objective of building a group of complimentary businesses that are entrepreneurial, innovative, globally focused and when operating together have the ability to generate better health outcomes and add value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor's assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.

# Biotech Capital.

## *Forward-looking Statements*

*This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Biotech Capital to be materially different from the statements in this announcement.*

## **For more information, please contact:**

Dr. Richard Treagus, Chairman  
[rtreagus@biotechcapital.com.au](mailto:rtreagus@biotechcapital.com.au)

+61 417 520 509